AstraZeneca announces new executive vice president
“I am delighted to welcome Pam to AstraZeneca at a very exciting time for our business,” AstraZeneca CEO Pascal Soriot said. “As our pipeline delivers, we will bring an increasing number of new medicines to patients across the globe over the coming years, including important biological therapies as our product mix shifts. Pam will be able to bring to bear her wealth of experience in manufacturing and supply chain management, as well as her experience in emerging markets, particularly China, a key priority for our company.”
Cheng succeeds David Smith, who is retiring after almost 10 years with AstraZeneca.
“I also want to take the opportunity to thank David Smith for the invaluable contribution he has made to the leadership of AstraZeneca and to streamlining and expanding our global manufacturing footprint,” Soriot said. “The quality, reliability and cost-effectiveness of our supply chain will be his legacy for many years to come.”
Cheng will report to Soriot and be a member of AstraZeneca’s Senior Executive Team. She joins AstraZeneca from Merck/MSD.